AGE & RESEARCH-USE CONFIRMATION
JD BioWorks supplies materials solely for qualified laboratory and analytical research. Products are not for human consumption or human or veterinary use.
Review the Terms and Conditions.
For Research Purposes Only. Not for human consumption or human or veterinary use.
JD BioWorks TB-500 research material. Available in 10 mg. For laboratory research only. Not for human or veterinary use.
Lot-specific analytical documentation: ILS Laboratories report COA-2026-ANGGNZ for lot 2026-002 reports 99.39% peptide purity by HPLC, identity confirmed, 10.45 mg net peptide content, and fentanyl not detected. Review the complete Certificate of Analysis below before use.
Storage: Follow the storage conditions stated on the released product label and lot-specific documentation.
Original price was: $60.00.$54.00Current price is: $54.00.
Availability: In stock
PAYMENT AT CHECKOUT
Choose from the payment methods available for your cart at checkout. For Zelle, placing the order creates an unpaid order; it does not send money. Open your own bank or Zelle app afterward and send the exact order total separately within 12 hours using the displayed recipient and order number. JD BioWorks ships only after the payment is received and manually verified. Pay by Bank continues to Finagy’s hosted ACH payment step.
Review the ACH/WEB authorizationTesting at a glance
Current lot documentation is published and available for review.
Fentanyl not detected
Product details
Specifications identify the catalog material. Lot-specific analytical results are reported separately in the current Certificate of Analysis.
An evidence-focused guide to GLOW research blend composition, lot-specific HPLC identity, 99.65% purity, measured component content, and limits of interpreting a three-peptide mixture.
Read Article
A field-by-field guide to the KLOW 80 mg lot 2026-002 Certificate of Analysis, including HPLC purity, identity, component quantitation, net blend content, terminology, and report limitations.
Read Article
A guide to the July 2026 peptide-compounding advisory votes and the difference between committee recommendations and FDA approval.
Read ArticleA neutral evidence review of TB-500, emphasizing the distinction from full-length thymosin beta-4 and the limits of available data.
Read ArticleVERIFIED-PURCHASE FEEDBACK
No verified-purchase reviews have been published for this product yet. JD BioWorks does not add placeholder, staff-written, or invented reviews.
